

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

Luis Manuel Martínez Vargas^{*1}, Isidro Fabián Martínez Valeriano², Juan Felipe Garibay Chávez³, Donaldo Emiliano Silva López⁴

¹Universidad Cuautemoc Aguascalientes plantel norte. Aguascalientes, Mexico.

²Universidad Autónoma de Aguascalientes. Aguascalientes, Mexico.

³Universidad Autónoma de Zacatecas. Zacatecas, Mexico.

⁴Tecnológico de Monterrey campus Monterrey. Monterrey, Mexico.

ABSTRACT

Electrical storm (ES), characterized by recurrent ventricular tachycardia or fibrillation refractory to conventional therapies, represents a critical medical emergency with substantial morbidity and mortality. The pathophysiological underpinnings of ES are intimately linked to heightened sympathetic tone and autonomic dysregulation, which perpetuate arrhythmogenesis. This extensive review synthesizes contemporary evidence on stellate ganglion blockade (SGB) as a neuromodulatory intervention for ES, examining its physiological rationale, procedural methodologies, and clinical outcomes. We integrate findings from pivotal studies, including institutional series and the recent large-scale prospective STAR study, to evaluate the safety profile and efficacy of both ultrasound-guided and anatomical landmark approaches. The analysis confirms that percutaneous SGB induces a rapid and significant reduction in arrhythmic burden, often serving as a crucial bridge to definitive therapy. Despite the absence of randomized controlled trials, the cumulative data from observational cohorts strongly support its integration into treatment algorithms for refractory ES, particularly in hemodynamically unstable patients where traditional options are limited or contraindicated. This review also addresses technical considerations, operator training, and future directions for research, emphasizing the need for standardized protocols and further investigation into long-term outcomes and patient selection criteria.

KEYWORDS: Electrical storm; stellate ganglion block; neuromodulation; ventricular tachycardia; ventricular fibrillation; sympathetic nervous system; autonomic modulation; refractory arrhythmia.

ARTICLE DETAILS

Published On:
02 May 2026

Available on:
<https://ijmscrs.com>

INTRODUCTION

The management of electrical storm (ES) persists as a formidable challenge in contemporary cardiology and electrophysiology. Defined as three or more episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) within a 24-hour period, ES portends a grim prognosis, with in-hospital mortality rates remaining elevated despite advances in pharmacological and device-based therapies. The syndrome often emerges in the context of structural heart disease, where a vicious cycle of sympathetic hyperactivity, myocardial ischemia, and electrical instability fosters a state of relentless arrhythmogenesis. Conventional therapeutic pillars, including beta-adrenergic blockade,

antiarrhythmic drugs, catheter ablation, and mechanical circulatory support, may prove insufficient or impractical in the acute setting, particularly among critically ill patients.

The seminal recognition of the autonomic nervous system's pivotal role in triggering and sustaining ventricular arrhythmias has catalyzed interest in targeted neuromodulation strategies. The stellate ganglion, a key nexus of sympathetic innervation to the heart, has emerged as a critical therapeutic target. Blockade of this structure, achieved via percutaneous injection of local anesthetic, aims to interrupt pathological sympathetic outflow, thereby raising the ventricular fibrillation threshold and stabilizing the myocardial substrate. Historically documented in isolated

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

case reports, the application of stellate ganglion blockade (SGB) for arrhythmia control has recently been substantiated by larger clinical experiences.

Early systematic reviews, such as that by Fudim et al. in 2017, aggregated initial case data, suggesting a pronounced reduction in arrhythmic events post-intervention. Subsequent institutional series, including work from the Mayo Clinic, further delineated the procedure's potential. However, heterogeneity in technique, outcome assessment, and patient selection limited generalizability. The recent publication of the prospective, multicenter STAR study represents a significant advancement, providing robust evidence on the effectiveness and safety of percutaneous SGB in over 130 patients, thereby addressing many prior methodological shortcomings.

This comprehensive review endeavors to consolidate the current body of knowledge on SGB for ES. We will delve into the neurocardiac mechanisms underpinning its efficacy, critically appraise the evolving technical approaches (including ultrasound-guided versus anatomical landmark techniques), and synthesize clinical outcome data from key studies. Furthermore, we will discuss its role within the broader treatment paradigm, considering its utility as a bridge to catheter ablation or surgical sympathectomy, and examine pertinent safety considerations, including performance in anticoagulated patients. By framing SGB within the context of modern autonomic therapeutics, this review aims to provide clinicians with a nuanced understanding of its indications, implementation, and emerging evidence base, while highlighting crucial gaps in knowledge that warrant future investigation.

Background

The relentless challenge of electrical storm (ES) underscores a profound intersection of structural cardiac pathology and dysregulated autonomic physiology. This malignant syndrome, characterized by clustered episodes of ventricular tachycardia or fibrillation, represents not merely an electrical crisis but a hemodynamic and metabolic catastrophe with dire prognostic implications. Its historical management has been a testament to the limitations of conventional antiarrhythmic strategies, which often falter against the backdrop of a hyperadrenergic state and a remodeled myocardial substrate. The evolution of therapeutic paradigms has gradually shifted from a purely cardiomyocentric view to one that acknowledges the critical orchestrating role of the cardiac nervous system.

The foundational link between sympathetic hyperactivity and ventricular arrhythmogenesis was established decades ago, demonstrating that catecholamine surges lower the ventricular fibrillation threshold and promote spatial dispersion of repolarization. In the setting of structural heart disease—be it ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy—this neural imbalance is exacerbated. A pathological positive feedback loop ensues: each arrhythmic

episode induces hemodynamic compromise, activating arterial baroreceptors and triggering a reflexive, yet detrimental, increase in sympathetic efferent traffic. This further precipitates myocardial ischemia, calcium overload, and triggered activity, fueling subsequent arrhythmias. This self-perpetuating cycle defines the physiopathological core of ES, rendering treatments that do not address this neuro-cardiac axis inherently incomplete.

Traditional therapeutic arsenals, including sequential or combined administration of beta-blockers, amiodarone, lidocaine, and deep sedation, alongside interventions like catheter ablation or mechanical circulatory support, form the standard of care. However, their efficacy is variable, and their application is often constrained by patient instability, drug intolerance, or procedural inaccessibility in urgent settings. Catheter ablation, while potentially curative, requires specialized expertise and stable hemodynamics, which are frequently absent during an ongoing storm. Similarly, the definitive intervention of surgical cardiac sympathetic denervation, though effective, is an invasive thoracic procedure not feasible in the acute, critically ill patient.

It is within this therapeutic gap that stellate ganglion blockade (SGB) has re-emerged as a compelling intervention. The stellate ganglion, representing the fusion of the inferior cervical and first thoracic ganglia, serves as the principal synaptic station for sympathetic efferent signals destined for the heart. Its percutaneous blockade with local anesthetic offers a targeted, rapid-onset means of interrupting this pathological sympathetic outflow. The initial evidence base was largely anecdotal, composed of case reports and small series that hinted at dramatic terminations of arrhythmic storms. These observations prompted more systematic inquiry.

The 2017 systematic review by Fudim et al. aggregated available case data, providing the first quantitative synthesis suggesting a significant reduction in ventricular arrhythmia burden following SGB. This was followed by several institutional case series that refined procedural techniques, predominantly favoring ultrasound-guided approaches for precision and safety. These studies collectively suggested that SGB could serve a dual purpose: as an emergent therapy to break the acute cycle of ES, and as a diagnostic probe to identify patients who might derive lasting benefit from permanent surgical denervation. However, questions regarding optimal technique, timing, patient selection, and generalizability persisted, limited by small sample sizes and single-center experiences.

The recent publication of the prospective, multicenter STAR study marks a pivotal advance in this field. By enrolling over 130 patients across 19 centers and standardizing operator training, it provided high-grade observational evidence for the profound antiarrhythmic efficacy and remarkable safety of percutaneous SGB, even in patients on dual antiplatelet or anticoagulant therapy. Its findings demonstrate a rapid, often complete, suppression of treated arrhythmic events,

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

substantiating the role of SGB as a crucial stabilizing bridge. Furthermore, it offered comparative insights into anatomical versus ultrasound-guided approaches, finding significant efficacy for both, thereby expanding procedural flexibility based on clinical context and resource availability.

Thus, the historical trajectory of SGB for ES has evolved from a sporadic rescue maneuver to a systematized component of the neuromodulation armamentarium. Its development mirrors a broader renaissance in understanding neuro-cardiac interactions, positioning autonomic modulation as a fourth pillar of arrhythmia management alongside drugs, devices, and ablation. The current evidence, while robust, continues to highlight the need for randomized controlled data to precisely define its place in therapy, optimize protocols, and uncover the biomolecular and neural remodeling effects that may explain its sometimes prolonged benefits beyond the pharmacological half-life of the injected anesthetic. This review synthesizes this evolving narrative, examining the anatomy, physiology, technique, and clinical evidence that now firmly anchor SGB in the management of refractory electrical storm.

Pathophysiology

The pathogenesis of electrical storm (ES) represents a complex and maladaptive confluence of structural myocardial vulnerability and profound autonomic dysregulation, culminating in a state of relentless ventricular arrhythmogenesis. At its core, ES is not a mere electrical epiphenomenon but rather the clinical manifestation of a destabilized neuro-cardiac axis, where the sympathetic nervous system transitions from a homeostatic regulator to a primary driver of life-threatening instability. This pathophysiological framework is essential for understanding the therapeutic rationale behind targeted interventions such as stellate ganglion blockade (SGB).

The substrate for ES is almost invariably a myocardium altered by disease. Ischemic cardiomyopathy, with its zones of infarcted tissue, border zone heterogeneity, and interstitial fibrosis, creates the anatomical and functional landscape for reentrant circuits. Similarly, non-ischemic cardiomyopathies, whether dilated, hypertrophic, or infiltrative, promote arrhythmogenesis through mechanisms of myocyte disarray, gap junction remodeling, and diffuse fibrotic scarring. This abnormal substrate exhibits heightened automaticity, triggered activity, and, most critically, the propensity for sustained reentry. However, the presence of structural heart disease alone is insufficient to explain the clustered, refractory nature of ES; it is the dynamic modulation of this substrate by the autonomic nervous system that ignites and perpetuates the storm.

Under normal conditions, sympathetic activation increases heart rate, enhances contractility, and facilitates atrioventricular conduction—adaptive responses to stress or exertion. In the diseased heart, however, this sympathetic output becomes spatially and temporally disordered. Post-myocardial infarction, for instance, there is evidence of

significant neural remodeling within the stellate ganglia themselves. Injured myocardium releases neurotrophic factors and inflammatory cytokines, such as nerve growth factor (NGF) and interleukin-6, which induce hyperinnervation, neuronal hypertrophy, and phenotypic switching within the ipsilateral stellate ganglion. This results in a population of neurons that are hyperexcitable and prone to ectopic firing, generating aberrant sympathetic signals even in the absence of central commands.

The initiation of an ES episode often follows a triggering event—myocardial ischemia, electrolyte imbalance, heart failure exacerbation, or even emotional distress—that provokes a catecholamine surge. This surge has multiple pro-arrhythmic consequences. At the cellular level, beta-adrenergic stimulation increases cyclic AMP, leading to elevated intracellular calcium via L-type calcium channels and the ryanodine receptor. This calcium overload promotes delayed afterdepolarizations (DADs), a key mechanism of triggered activity. Furthermore, sympathetic stimulation abbreviates action potential duration heterogeneously across the myocardium, particularly in the infarct border zone, increasing the dispersion of repolarization and lowering the threshold for reentry. The resulting ventricular tachycardia or fibrillation then instigates a vicious, self-amplifying cycle.

This cycle is central to the pathophysiology of ES. Each arrhythmic episode, depending on its rate and duration, causes acute hemodynamic compromise. The ensuing hypotension and reduced coronary perfusion are sensed by arterial baroreceptors, which, in a compensatory reflex, further amplify sympathetic efferent outflow from the medulla oblongata via the stellate ganglia. This creates a massive, localized release of norepinephrine in the cardiac synaptic clefts, exacerbating the very conditions that precipitated the initial arrhythmia. Concurrently, the mechanical stretch and ischemia from the arrhythmia activate cardiac sympathetic afferent fibers. These afferent signals, projecting back to the dorsal horn of the spinal cord and the stellate ganglion, can initiate positive feedback loops at the ganglionic level, bypassing central inhibition and leading to sustained, decentralized sympathetic excitation. This creates a state of "autonomic storm" that parallels and fuels the electrical storm.

The stellate ganglion, therefore, occupies a pivotal position in this pathological cascade. It acts as the final common pathway and an active participant in the dysrhythmic process. Its blockade with local anesthetic achieves therapeutic effect through several interrelated mechanisms. The primary and most immediate effect is the pharmacological interruption of efferent sympathetic traffic to the heart, effectively raising the ventricular fibrillation threshold and suppressing triggered activity. However, evidence suggests the benefits of SGB may extend beyond this simple conduction block. By also silencing afferent signaling from the inflamed or ischemic heart, SGB can disrupt the spinal reflex arcs that sustain ganglionic hyperactivity. There is emerging speculation that

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

the injection of anesthetic into the periganglionic space may exert neuromodulatory effects, perhaps through anti-inflammatory actions on the ganglion itself, potentially resetting a maladapted neural network. This could explain the clinical observation, noted in studies like the STAR trial and earlier series, that the antiarrhythmic effect of a temporary SGB often persists for hours or days beyond the known pharmacokinetic duration of the local anesthetic used, hinting at an interruption of the pathological remodeling process itself.

In summary, the pathophysiology of ES is a textbook example of a feed-forward pathological loop where a vulnerable myocardial substrate and a dysregulated, hyperactive sympathetic nervous system engage in a mutually reinforcing dance of dysfunction. The stellate ganglion serves as both the conductor and a key amplifier within this circuit. Consequently, its targeted blockade represents a physiologically rational intervention, aiming not just to suppress a symptom but to disrupt the core mechanistic cycle sustaining the electrical storm. This profound understanding of the neuro-cardiac interface underpins the resurgence of SGB as a targeted, mechanism-based therapy in the modern management of refractory ventricular arrhythmias.

Indications and Contraindications

The integration of stellate ganglion blockade (SGB) into the therapeutic algorithm for electrical storm (ES) necessitates a nuanced understanding of its specific indications and the clinical scenarios where its application may be inadvisable or require heightened caution. As a neuromodulatory intervention targeting the sympathetic axis, its role is defined not by broad, first-line application, but by strategic deployment within a hierarchy of escalating therapies for refractory ventricular arrhythmias. The evolution of evidence, particularly from larger observational cohorts like the STAR study, has helped crystallize these clinical boundaries, moving SGB from an anecdotal rescue therapy toward a more standardized component of care for specific, high-acuity patient phenotypes.

The paramount indication for SGB is the presentation of refractory electrical storm, a scenario characterized by recurrent episodes of sustained ventricular tachycardia or fibrillation that persist despite initial conventional medical management. This refractoriness is typically defined by the failure of, or intolerance to, a sequence of interventions. The patient will often have received aggressive beta-adrenergic blockade, frequently with intravenous agents, and at least one, and commonly multiple, parenteral antiarrhythmic drugs such as amiodarone, lidocaine, or procainamide. The persistence of arrhythmic storms in this context signifies a profound sympathetic drive that is pharmacologically resistant, thereby creating the pathophysiological rationale for direct autonomic intervention. SGB serves as a critical bridge in this setting, aiming to achieve acute electrical stabilization. This stabilization can serve multiple subsequent purposes: it can provide a necessary window of hemodynamic

and electrical calm to safely facilitate definitive catheter ablation, allow for the optimization of mechanical circulatory support (such as with an intra-aortic balloon pump or extracorporeal membrane oxygenation), or serve as a diagnostic probe. In the latter role, a positive response to a temporary SGB can help identify patients whose arrhythmic substrate is sympathetically mediated and who may therefore derive significant long-term benefit from a permanent surgical cardiac sympathetic denervation.

Beyond the scenario of clear pharmacological failure, SGB is increasingly considered in situations of acute clinical urgency where standard therapies are either contraindicated or logistically delayed. For instance, in the patient presenting with ES and concurrent cardiogenic shock, the hemodynamic compromise induced by high-dose beta-blockers or certain antiarrhythmics may be prohibitive. SGB, by directly modulating sympathetic tone at the ganglionic level without significant systemic negative inotropic effects, can offer an alternative pathway to arrhythmia control. Similarly, in the setting of acute intoxication with sympathomimetic agents or in conditions like Takotsubo cardiomyopathy, where catecholamine excess is a central driver, SGB can provide targeted antagonism of the pathological autonomic outflow. The STAR study further highlighted the feasibility of SGB in patients who are actively anticoagulated, a population in whom more invasive neural interventions like thoracic epidural anesthesia carry substantial bleeding risks. This expands its utility to a broad cohort of patients with structural heart disease who are routinely on antithrombotic regimens. However, the application of SGB is not without boundaries, and a clear understanding of contraindications is mandatory to ensure patient safety. Absolute contraindications are few but critical. Active infection at the intended injection site in the anterior cervical or supraclavicular region is an absolute prohibition due to the risk of seeding a deep neck infection or causing an abscess. A known severe allergy to amide- or ester-type local anesthetics, depending on the agent planned for use, similarly precludes the procedure. Coagulopathy, while historically considered an absolute contraindication for regional anesthetic techniques, has been contextually re-evaluated. Evidence from the STAR study, where a majority of procedures were performed on patients receiving single, dual, or even triple antithrombotic therapy, suggests that with appropriate technique—particularly the use of smaller-gauge needles and perhaps ultrasound guidance to avoid vascular structures—the procedure can be performed with an acceptable and remarkably low risk of significant hematoma. Therefore, coagulopathy or therapeutic anticoagulation is now more accurately considered a relative contraindication, demanding a careful risk-benefit analysis, operator expertise, and perhaps a preference for ultrasound-guided over blind anatomical approaches to minimize vascular trauma.

Several important relative contraindications and considerations necessitate careful clinical judgment. Anatomical distortions of the neck, whether from prior

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

surgery (such as thyroidectomy or carotid endarterectomy), radiation fibrosis, significant cervical osteoarthritis, or the presence of a large goiter, can obscure landmarks, displace normal anatomy, and increase the technical difficulty and risk of complications like intravascular injection, esophageal puncture, or neural injury. In such cases, if SGB is deemed essential, the use of real-time ultrasound guidance is strongly favored, if not mandatory, to visually navigate the altered anatomy. The presence of pre-existing neurological deficits, such as contralateral phrenic nerve palsy or recurrent laryngeal nerve dysfunction, warrants caution, as an ipsilateral block could potentially result in bilateral impairment with serious respiratory consequences. Glaucoma has been traditionally listed as a relative contraindication due to theoretical concerns about the unilateral Horner's syndrome (ptosis, miosis, anhidrosis) that commonly results from a successful block; however, in the life-threatening context of ES, this transient side effect is almost always an acceptable trade-off, though discussion with the patient or surrogate is prudent.

A final, often overlooked consideration is the lack of immediate access to resuscitative equipment and expertise. While SGB is a bedside procedure, its performance in the vicinity of major vascular and neural structures carries inherent risks, including local anesthetic systemic toxicity (LAST), intravascular injection, vertebral artery injury, or high spinal anesthesia if the injectate tracks into the neuraxis. Therefore, the procedure should only be undertaken in an environment where personnel are trained in advanced cardiac life support and where lipid emulsion therapy and other emergency medications are immediately available to manage potential complications. In summary, the indications for SGB in ES are firmly rooted in the failure of conventional antiadrenergic and antiarrhythmic therapy, while its contraindications emphasize anatomical safety, allergy, and procedural setting, with a modern, evidence-based reassessment of risks in anticoagulated patients guiding its expanded use in contemporary practice.

CONCLUSION

The convergence of clinical urgency and physiological insight has propelled stellate ganglion blockade from an obscure intervention to a cornerstone of contemporary management for refractory electrical storm. This extensive review has traversed the anatomical, pathophysiological, and clinical landscape that defines its application, underscoring its emergence not as a mere procedural alternative, but as a targeted neuromodulatory strategy addressing the core sympathetic dysregulation perpetuating malignant ventricular arrhythmias. The cumulative evidence, now significantly anchored by robust multicenter prospective data, delineates a compelling narrative of efficacy and safety that challenges historical therapeutic hierarchies.

The mechanistic rationale for SGB is firmly established within the neuro-cardiac paradigm of electrical storm. By

interrupting the efferent limb of a maladaptive sympathetic reflex arc—and potentially modulating aberrant afferent signaling and ganglionic remodeling—SGB achieves a rapid stabilization of the myocardial substrate. This action transcends simple pharmacological effect, often yielding an antiarrhythmic benefit that extends beyond the pharmacokinetic half-life of the administered local anesthetic. Clinically, this translates into the dramatic reductions in treated arrhythmic episodes and defibrillation shocks documented across studies, providing the crucial hemodynamic and electrical reprieve necessary to facilitate definitive therapies or bridge patients through acute, reversible insults.

Technological and methodological refinements have been pivotal in its adoption. The development and standardization of ultrasound-guided techniques have enhanced precision and safety, allowing for direct visualization of needle trajectory, avoidance of vascular structures, and confirmation of anesthetic spread, even in patients with challenging anatomy or on therapeutic anticoagulation. Concurrently, the perseverance of the landmark anatomical approach retains vital utility in resource-limited or time-critical scenarios, such as during active cardiac arrest. The demonstrated efficacy of both modalities, as highlighted in the STAR study, affords clinicians essential flexibility. Furthermore, the establishment of structured training protocols and quality metrics is dissipating the aura of exclusivity that once surrounded the procedure, promoting its safe dissemination beyond specialized academic centers.

Nevertheless, the integration of SGB into standardized treatment algorithms occurs within a context of recognized evidentiary boundaries. The absence of data from large-scale randomized controlled trials precludes definitive statements on its impact on hard endpoints like long-term mortality or its comparative effectiveness against other advanced interventions like thoracic epidural anesthesia or early aggressive ablation. These trials are an urgent necessity. Future research must also strive to elucidate the precise biomolecular and neural remodeling effects induced by the block, to identify predictive biomarkers of response, and to optimize protocols regarding anesthetic agents, dosing, and the role of continuous infusion catheters for sustained effect. In conclusion, percutaneous stellate ganglion blockade represents a paradigm-shifting intervention in the acute management of refractory electrical storm. It is a procedure grounded in a sophisticated understanding of autonomic physiology, validated by a growing body of high-quality observational evidence, and characterized by a favorable risk-benefit profile even in complex, critically ill patients. While it does not replace established therapies, it has irrevocably earned its place as a powerful adjunct and a strategic bridge within the multidisciplinary armamentarium. As clinical experience broadens and research addresses persistent questions, SGB is poised to evolve from an emergent salvage therapy to a systematically deployed standard of care,

Stellate Ganglion Blockade in Electrical Storm: A Comprehensive Review

fundamentally altering the therapeutic trajectory for patients caught in the relentless tempest of the electrical storm. Its story exemplifies the progress achieved when clinical innovation is directly guided by a deepening comprehension of disease pathophysiology.

REFERENCES

- I. Al-Khatib, S. M. et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the Prevention of Sudden Cardiac Death. *Circulation*. 138, e272–e391. <https://doi.org/10.1161/CIR.0000000000000549> (2018).
- II. Deyell, M. W. et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients With Structural Heart Disease. *Canadian Journal of Cardiology* 36, 822–836, doi: (2020). <https://doi.org/10.1016/j.cjca.2020.04.004> (2020).
- III. Zeppenfeld, K. et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal* 43, 3997–4126, doi: (2022). <https://doi.org/10.1093/eurheartj/ehac262> (2022).
- IV. Jentzer, J. C. et al. Multidisciplinary critical Care Management of Electrical Storm. *J. Am. Coll. Cardiol.* 81, 2189–2206. <https://doi.org/10.1016/j.jacc.2023.03.424> (2023).
- V. Guerra, F. et al. Implantable cardioverter-defibrillator programming and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD). *Heart Rhythm*. 13, 1987–1992 (2016).
- VI. Bode, F., Wiegand, U., Raasch, W., Richardt, G. & Potratz, J. Differential effects of defibrillation on systemic and cardiac sympathetic activity. *Heart*. 79, 560–567. <https://doi.org/10.1136/hrt.79.6.560> (1998).
- VII. Nademanee, K., Taylor, R., Bailey, W. E., Rieders, D. E. & Kosar, E. M. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. *Circulation*. 102, 742–747. <https://doi.org/10.1161/01.cir.102.7.742> (2000).
- VIII. Chatzidou, S. et al. Propranolol Versus Metoprolol for treatment of electrical storm in patients with Implantable Cardioverter-Defibrillator. *J. Am. Coll. Cardiol.* 71, 1897–1918. <https://doi.org/10.1016/j.jacc.2018.02.056> (2018).
- IX. Gadhinlajkar, S., Sreedhar, R., Unnikrishnan, M. & Namboodiri, N. Electrical storm: role of stellate ganglion blockade and anesthetic implications of left cardiac sympathetic denervation. *Indian J. Anaesth.* 57, 397–400. <https://doi.org/10.4103/0019-5049.118568> (2013).
- X. Vaseghi, M. & Shivkumar, K. The role of the autonomic nervous system in sudden cardiac death. *Prog. Cardiovasc. Dis.* 50, 404 (2008).
- XI. Martins, R. P. et al. Effectiveness of deep sedation for patients with intractable electrical storm refractory to antiarrhythmic drugs. *Circulation*. 142, 1599–1601. <https://doi.org/10.1161/CIRCULATIONAHA.120.047468> (2020).
- XII. Baldi, E. et al. Contemporary management of ventricular electrical storm in Europe: results of a European Heart Rhythm Association Survey. *EP Europace*. 25, 1277–1283. <https://doi.org/10.1093/europace/euac151> (2022).
- XIII. Zandstra, T. E. et al. Asymmetry and heterogeneity: Part and Parcel in Cardiac autonomic innervation and function. *Front. Physiol.* 12 <https://doi.org/10.3389/fphys.2021.665298> (2021).
- XIV. Narouze, S., Vydyanathan, A. & Patel, N. Ultrasound-guided stellate ganglion block successfully prevented esophageal puncture. *Pain Physician*. 10, 747–752 (2007).